Pfizer and Moderna conducting trials of their vaccines in children 12 and older and hope to have findings by the summer
FRIDAY, Feb. 12, 2021 (HealthDay News) — Late summer will be the earliest that children in the United States could receive COVID-19 vaccines, experts say.
Pfizer and Moderna are conducting clinical trials of their vaccines in children 12 and older and hope to have findings by the summer, The New York Times reported. Depending on the results, the companies may then test them in younger children. It typically takes the U.S. Food and Drug Administration a few weeks to review data from a clinical trial and approve a vaccine. Johnson & Johnson, Novavax, and AstraZeneca also plan to test their COVID-19 vaccines in children, but are not as far along as the other two companies.
About one-quarter of the U.S. population is younger than 21, but that age group accounts for less than 1 percent of COVID-19 deaths. However, about 2 percent of children with COVID-19 do have to be hospitalized, and at least 227 children in the United States have died of the disease.
“It is a significant disease in children, just not necessarily when you compare it to adults,” Kristin Oliver, M.D., a pediatrician and vaccine expert at Mount Sinai Hospital in New York City, told The Times.
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health
Autism Spectrum Disorder Diagnoses Increased for Females Since 2020
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators
Addition of CAC to PREVENT-ASCVD Equations May Improve Predictive Utility in Certain Patients